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Abstract 
Thrombin, a serine protease essential for blood coagulation, also plays an important role 
in cellular injury associated with intracerebral hemorrhage.  Here we show that, in 
organotypic cortico-striatal slice cultures, thrombin evoked delayed neuronal injury in the 
cerebral cortex and shrinkage of the striatum.  These effects were prevented by 
cycloheximide and actinomycin D but not by a caspase-3 inhibitor.  Thrombin-induced 
shrinkage of the striatum was abolished by a thrombin inhibitor argatroban or prior heat 
inactivation of thrombin, and significantly attenuated by a protease-activated receptor-1 
antagonist FR171113.  However, thrombin-induced cortical injury was not prevented either 
by heat inactivation or by FR171113, and was only partially inhibited by argatroban.  In 
addition, inhibition of extracelluar signal-regulated kinase (ERK), Src tyrosine kinase and 
protein kinase C prevented both neuronal injury in the cortex and shrinkage of the striatum, 
whereas inhibition of p38 mitogen-activated protein kinase and c-Jun N-terminal kinase 
prevented shrinkage of the striatum only.  Thrombin treatment promptly induced 
phosphorylation of ERK, which was not prevented by inhibition of Src and protein kinase C.  
Thus, thrombin induces cellular injury in the cerebral cortex and the striatum, by recruiting 
multiple and distinct signaling pathways in protease activity-independent as well as dependent 
manner. 
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Introduction 
Thrombin, a serine protease generated from prothrombin at sites of vascular injury, plays 
an important role in blood coagulation and wound healing.  Prothrombin mRNA is also 
expressed in various brain regions (Dihanich et al., 1991), which indicates that thrombin may 
play a role as a signaling molecule in the central nervous system.  Indeed, members of 
protease-activated receptor (PAR) family that mediate biological actions of thrombin are 
distributed widely throughout the central nervous system.  Thrombin cleaves amino terminal 
exodomain of PAR-1, -3 and -4, and the newly generated amino terminus binds to the 
extracellular domain of the receptor as a tethered ligand (Noobakhsh et al., 2003).  PARs are 
G protein-coupled receptors with seven transmembrane segments.  Activation of these 
receptors leads to various kinds of intracellular signal transduction, including increase of 
intracellular calcium (Smith-Swintosky et al., 1995), decrease of cyclic AMP (Yang et al., 
1997) and activation of protein kinase C (PKC) (Wang et al., 2002).  In addition, several 
lines of evidence suggest that mitogen-activated protein kinases (MAPKs) are involved in 
thrombin-induced cellular responses (Marinissen et al., 2003; Suo et al., 2003; Wang et al., 
2002). 
At low concentrations, thrombin may provide cytoprotective effects on neurons and 
astrocytes against oxidative stress and ischemic injury (Donovan and Cunningham, 1998; 
Striggow et al., 2000; Vaughan et al., 1995).  By contrast, uncontrolled thrombin activity 
after intracerebral hemorrhage results in gliosis and neural cell death.  For example, 
experimental evidence in vitro has shown that thrombin causes neurite retraction in 
differentiated neural cell lines (Jalink and Moolenaar, 1992), and cell death in dissociated 
neuron cultures and cultured hippocampal slices (Donovan et al., 1997; Striggow et al., 2000; 
Suo et al., 2003).  Intrastriatal injection of thrombin causes neuronal degeneration in vivo 
(Xue et al., 2001), and neuronal injury and neurological dysfunction associated with 
3 
intracerebral hemorrhage are ameliorated by argatroban, a thrombin inhibitor (Kitaoka et al., 
2002).  Moreover, thrombin may also play a pivotal role in other pathological conditions 
including ischemic stroke, traumatic injury and Alzheimer’s disease (Xi et al., 2003; Christov 
et al., 2004). 
Despite these lines of evidence, little information is available concerning signaling 
mechanisms mediating cytotoxic actions of thrombin.  Thrombin-induced neuronal death 
exhibits features of apoptosis (Donovan et al., 1997; Smirnova et al., 1998; Turgeon et al., 
1998), and caspase inhibitors attenuate thrombin-induced cell death (Choi et al., 2003a; 
Turgeon et al., 1998).  Activation of extracelluar signal-regulated kinase (ERK), a kind of 
MAPKs, appears to be involved in thrombin-induced cell death in primary hippocampal 
neuron cultures (Suo et al., 2003).  On the other hand, in the midbrain substantia nigra, 
thrombin induces degeneration of dopaminergic neurons indirectly via activation of microglia, 
which may involve several members of MAPK family such as ERK, p38 MAPK and c-Jun 
N-terminal kinase (JNK) (Choi et al., 2003a, 2003b; Lee et al., 2005).  Contribution of 
multiple signaling mechanisms may differ among different experimental conditions and 
cellular contexts. 
Intracerebral hemorrhage occur preferentially in several brain regions including the 
cerebral cortex and the striatum, but the detailed mechanisms of thrombin-induced injury in 
these brain regions remain to be determined.  In this study, we investigated cytotoxic 
consequences of thrombin application to organotypic cortico-striatal slice cultures. 
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Materials and methods 
Drugs and chemicals 
Drugs and chemicals were obtained from Nacalai Tesque (Kyoto, Japan), unless otherwise 
indicated.  Thrombin from bovine plasma (catalog No. T4648) was obtained from Sigma (St. 
Louis, MO, USA).  Three different lots (022K7604, 061K7612 and 023K7602) of thrombin 
gave similar results.   Bovine serum albumin (catalog No. A2153), MK-801, 
aminoguanidine, Nω-nitro-L-arginine methyl ester (L-NAME), N-acetylcysteine (NAC) and 
clodronate were also obtained from Sigma.  Cell-permeable DEVD-CHO, PD98059, U0126, 
SB203580, bisindolylmaleimide (BIM), 
4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2) and 
2-cyano-(3,4-dihydroxy)-N-benzylcinnamide (AG490) were obtained from Calbiochem (San 
Diego, CA, USA).  SP600125 were obtained from Tocris Cookson (Bristol, UK).  
Cycloheximide and glutathione were obtained from Wako Pure Chemicals (Osaka, Japan).  
Argatroban was obtained from Sawai Pharmaceuticals (Osaka, Japan).  FR171113 was a 
kind gift from Fujisawa Pharmaceuticals (Osaka, Japan).   
 
Preparation of slice cultures 
All experimental procedures were approved by our institutional animal experimentation 
committee, and animals were treated in accordance with the guidelines of the NIH regarding 
the care and use of animals for experimental procedures.  We prepared organotypic slice 
cultures according to the methods described previously (Fujimoto et al., 2004).  Briefly, 
Wistar rats at postnatal days 3 - 4 (Nihon SLC, Shizuoka, Japan) were anesthetized by 
hypothermia, brains were removed from the skull and separated into two hemispheres.  Each 
hemisphere was cut into coronal slices of 300 μm thickness under sterile conditions.  Slices 
containing the parietal cortex and the striatum were chosen, and other brain structures such as 
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the septum and the basal forebrain were removed from each slice.  Six cortico-striatal tissue 
slices were transferred onto a 30-mm Millicell-CM insert membrane (Millipore, Bedford, MA, 
USA) in six-well plates.  Culture medium, consisting of 50% minimum essential 
medium/HEPES (GIBCO, Invitrogen Japan, Tokyo, Japan), 25% Hanks’ balanced salt 
solution (GIBCO) and 25% heat-inactivated horse serum (GIBCO) supplemented with 6.5 
mg/ml D-glucose and 2 mM L-glutamine, 100 U/ml penicillin G potassium and 100 μg/ml 
streptomycin sulfate (GIBCO), was supplied at 0.75 ml/well so that the slices were 
maintained at liquid/air interface.  Culture medium was exchanged for fresh one on the next 
day of culture preparation, and thereafter, every two days.  Slices were cultured in a 
humidified atmosphere of 5% CO2 and 95% air at 34°C. 
 
Drug treatment and cell death assessment 
Cultured slices at 9 - 11 days in vitro were incubated for 24 - 48 h in serum-free medium, 
where minimum essential medium/HEPES substituted for horse serum.  Then slices were 
exposed to thrombin and other drugs dissolved in serum-free medium for indicated periods.  
To assess cell injury, propidium iodide (PI; 5 μg/ml) was added to serum-free medium for 
drug treatment.  After indicated periods, PI fluorescence of each slice was observed with an 
inverted fluorescence microscope with a rhodamine filter set and a 10× objective lens.  
Fluorescence images were captured through a monochrome chilled CCD camera (C5985; 
Hamamatsu Photonics, Hamamatsu, Japan) and stored as image files.  The intensity of each 
pixel was expressed as an 8-bit signal (0 - 255), and the average signal intensity in an area of 
180 μm × 180 μm within the parietal cortex was obtained as the fluorescence value of each 
slice, with the use of NIH Image 1.63 software.  In each experiment, slice cultures treated 
with 100 μM N-methyl-D-aspartate (NMDA) for 72 h were used to determine the degree of 
the standard injury.  Fluorescence values were normalized with the intensity of cultures that 
6 
received standard injury as 100%.  Images of whole slice cultures were also obtained 
through a 1× objective lens, and the area of the striatal region in each slice was estimated with 
NIH Image 1.63. 
 
Immunohistochemistry and nuclear staining 
After drug treatment, slice cultures were fixed with 0.1 M phosphate buffer containing 4% 
paraformaldehyde and 4% sucrose for 2 h.  After rinse with phosphate-buffered saline (PBS), 
they were permeabilized and blocked by 0.1% Triton X-100 in PBS containing 1.5 % horse 
serum or goat serum, then incubated with primary antibodies overnight at 4°C.  Primary 
antibodies were mouse anti-NeuN (1:200, Chemicon International, Temecula, CA, USA), 
mouse anti-OX42 (1:300, Dainippon Pharmaceutical, Osaka, Japan), mouse anti-glial 
fibrillary acidic protein (GFAP) (1:500, Sigma), and rabbit anti-phospho-p44/42 MAP kinase 
(T202/Y204) (1:250, Cell Signaling Technology, Beverly, MA, USA).  After rinse with PBS, 
cultures were incubated with secondary antibodies for 1 h at room temperature.  Alexa Fluor 
568-labeled goat anti-rabbit IgG (1:1000, Molecular Probes, Eugene, OR, USA), Alexa Fluor 
488-labeled goat anti-mouse IgG (1:1000, Molecular Probes), Alexa Fluor 568-labeled goat 
anti-mouse IgG (1:1000, Molecular Probes), Cy2-conjugated goat anti-rabbit IgG (1:1600, 
Jackson Immunoreseach Laboratories, West Grove, PA, USA) and Cy3-conjugated goat 
anti-mouse IgG (1:1600, Jackson Immunoreseach Laboratories) were used as secondary 
antibodies.  In several experiments, Alexa Fluor 488-conjugated isolectin GS-IB4 from 
Griffonia simplicifolia (1 μg/ml, Molecular Probes) was added to the secondary antibody 
solution.  Then cultures were rinsed with PBS and specimens were dehydrated through a 
graded series of ethanol and mounted on slide glasses with glycerol.  Fluorescence signals 
were observed with a laser-scanning confocal microscopic system (MRC1024, Biorad, 
Hercules, CA, USA). 
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In several experiments, cell nuclei were stained with Hoechst 33342 (Molecular Probes).  
Cultures fixed with 4% paraformaldehyde as mentioned above were incubated with 0.1 mg/ml 
Hoechst 33342 for 60 min.  After wash with PBS, fluorescence images were acquired 
through an upright epifluorescence microscope. 
 
Nitrite quantification 
 Amount of nitric oxide released during treatment with thrombin was quantified as a 
concentration of nitrite in culture medium (Shibata et al., 2003).  Culture supernatants (100 
μl) were subjected to a reaction with an equal volume of Griess reagent (1% sulfanilamide 
and 0.1% N-(1-naphthyl)-ethylenediamine dihydrochloride in 2.5% phosphoric acid) for 10 
min at room temperature.  Absorbance of diazonium compound was measured at 540 nm on 
a microplate reader.  Absolute levels of nitrite were determined with reference to a standard 
curve obtained from defined concentrations of sodium nitrite. 
 
Western blot analysis 
After treatment with thrombin and drugs for indicated periods, slice cultures were 
harvested and homogenized in ice-cold lysis buffer containing 20 mM Tris-HCl (pH 7.0), 25 
mM β–glycerophosphate (Sigma), 2 mM EGTA·2Na, 1% Triton X-100, 1 mM vanadate, 1% 
aprotinin (Sigma), 1 mM phenylmethylsulfonyl fluoride and 2 mM dithiothreitol.  Samples 
were mixed with a sample buffer composed of 124 mM Tris-HCl (pH 6.8), 4% sodium 
dodecyl sulfate (SDS), 10% glycerol, 0.02% bromophenol blue and 4% 2-mercaptoethanol.  
After boiling for 5 min, samples were subjected to 12% SDS-polyacrylamide gel 
electrophoresis for 70 min, followed by transfer to PVDF membrane (Millipore) for 70 min.  
Membranes were blocked for at least 1 h by 5% nonfat milk at room temperature and 
subsequently incubated overnight with mouse anti-phospho-p44/42 MAP kinase (T202/Y204) 
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(1:2000, Cell Signaling Technology), anti-p44/42 MAP kinase (1:1000, Cell Signaling 
Technology) and goat anti-β–actin (1:3000, Santa Cruz Biotechnology, Santa Cruz, CA, USA).  
The membranes were rinsed and incubated with horseradish peroxidase-conjugated goat 
anti-mouse IgG (1:10000, Jackson Immunoreseach Laboratories), goat anti-rabbit IgG 
(1:10000, Jackson Immunoreseach Laboratories) and horse anti-goat IgG (1:10000, Vector 
Laboratories, Burlingame, CA, USA).  After incubation with secondary antibodies, 
membranes were rinsed and bound antibodies were detected with enhanced 
chemiluminescence kit (Amersham Biosciences, Buckinghamshire, UK) according to the 
manufacturer’s instructions.  The band intensities were analyzed with NIH image 1.63. 
 
Statistics 
Data are expressed as means ± S.E.M.  Statistical significance of difference was 
evaluated with one-way analysis of variance followed by Student–Newman–Keuls’ test.  
Probability values less than 5% were considered significant. 
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Results 
Thrombin induces delayed cortical neuron death and striatal degeneration 
Cortico-striatal slices were maintained for 9 - 11 days in culture.  As previously 
described (Fujimoto et al., 2004), the striatal region gradually flattened during cultivation and 
typically left monolayer of cells, whereas the cortical region maintained much thicker 
appearance than the striatal region.  These cultures were exposed to thrombin at 
concentrations of 10 - 300 U/ml for 72 h, and PI fluorescence was used as a measure of cell 
injury.  We could also observe the entire morphology of individual slices probed by faint 
background fluorescence of PI (Fig. 1A-L). 
Thrombin induced two prominent changes in cortico-striatal slice cultures.  First, in the 
cortical region, we observed a drastic increase in PI fluorescence indicating cell death.  The 
cytotoxic effect of thrombin in the cortex was evident at concentrations of 100 and 300 U/ml.  
Cell death occurred in a delayed manner: thrombin at 100 U/ml did not show cytotoxic effect 
at 24 h, and a robust increase in PI fluorescence was observed at 72 h after the onset of 
thrombin exposure (Fig. 1Q).  Second, shrinkage of the tissue was observed in a delayed 
manner.  Particularly, the area of the striatal region displayed a marked decrease in response 
to treatment with 100 and 300 U/ml thrombin for 48 - 72 h.  A lower concentration (30 
U/ml) of thrombin also caused a significant decrease in the striatal area after 72 h of treatment 
(Fig. 1R).  The shrinkage seemed to be initiated by focal detachment of the tissue, 
concomitantly with cell death around the corresponding area (Fig. 1M, N).  We did not 
determine which cell types underwent cell death in this area, because detached tissue was 
difficult to be examined immunohistochemically, and also because tissue detachment per se 
was likely to induce cell death that may obscure the conclusion.  The rest of the striatal 
region that remained attached to the membrane contained viable neurons, astrocytes and 
microglia (data not shown), which did not support the possibility that selective loss of a 
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particular type of cells in the striatal region accounts for the shrinkage.  In contrast, we never 
observed shrinkage of cortico-striatal tissues after treatment with NMDA (Fig. 1O, P).  
Striatal injury after NMDA application observed by macroscopic PI fluorescence (Fig. 1P) 
was not so clear as cortical injury, because the striatal region consisted of much thinner layer 
of cells than the cortical region, and also because some populations of the striatal neurons 
were resistant to NMDA cytotoxicity.  We confirmed by close examination that PI-positive 
cells appeared in the striatal region after NMDA treatment.  Bovine serum albumin, at a 
protein concentration corresponding to that of 100 U/ml of thrombin, did not show any 
cytotoxic effects on the cortical and the striatal regions (data not shown). 
To identify cell types that caused cell death in the cortical region in response to thrombin, 
we performed immunohistochemical examinations using antibodies against cell type-specific 
marker proteins such as NeuN (a neuronal marker), OX42 (a microglial marker) and GFAP 
(an astrocyte marker).  We found that numerous NeuN-positive cells were present in the 
cortical region of slice cultures without thrombin treatment, whereas application of thrombin 
to the cultures for 72 h caused a marked decrease in the number of immunoreactive cells (Fig. 
2A, B).  We also performed NeuN immunohistochemistry on slices after uptake of PI, 
according to the method of Brana et al. (2002).  We observed co-localization of PI 
fluorescence and NeuN immunoreactivity, which indicated that these dying cells were 
neurons.  Several PI-positive cells were not stained or were only weakly stained by NeuN, 
which may be in part due to loss of immunoreactivity during progression of degeneration 
processes (arrows in Fig. 2B).  Interestingly, double fluorescence examinations revealed that 
a significant population of OX42-positive microglia also contained PI fluorescence (Fig. 2D).  
After thrombin treatment, the number of OX42-immunoreactive cells did not decrease, but the 
morphology of these cells changed from resting ramified form into activated amoeboid form 
(Fig. 2C, D).  Therefore, co-localization of PI fluorescence and OX42 immnoreactivity 
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might reflect phagocytic activity of activated microglia on dying neurons.  To examine this 
possibility, we utilized fluorophore-labeled isolectin GS-IB4 to identify microglia and 
compared the pattern of isolectin staining with that of NeuN immunoreactivity.  No 
isolectin-positive cells engulfed NeuN-positive cells at 48 - 72 h after thrombin exposure (Fig. 
2G, H), indicating that PI- and OX42-positive cells (Fig. 2D) represent dying microglia rather 
than microglia incorporating dying neurons.  In contrast to these observations, no 
co-localization of PI fluorescence with GFAP immunoreactivity was apparent (Fig. 2E, F).  
These results suggest that the dying cell population in the cortical region of slice cultures after 
thrombin treatment consists mainly of neurons and also includes microglia. 
 
Thrombin cytotoxicity exhibits several features of apoptosis but is independent of caspase-3 
Several studies reported that thrombin induces apoptosis of neuronal as well as 
non-neuronal cells (Donovan et al., 1997), and that caspase inhibitors block thrombin 
cytotoxicity (Smirnova et al., 1998; Turgeon et al., 1998).  Accordingly, we examined if 
apoptotic processes are involved in thrombin toxicity in cortico-striatal slice cultures.  First, 
morphological changes in cell nuclei after thrombin treatment were examined by nuclear 
staining with Hoechst 33342.  As shown in Fig. 3A, nuclei of cells bearing diffuse staining 
with the Hoechst dye exhibited round or oval morphology in untreated slice cultures.  In 
contrast, a number of condensed and fragmented nuclei appeared in slices treated with 100 
U/ml thrombin for 72 h (Fig. 3B).  Second, we examined if macromolecule synthesis was 
required for thrombin cytotoxicity.  Concomitant application of cycloheximide (1 μg/ml), a 
protein synthesis inhibitor, with thrombin abolished cell death in the cortical region (Fig. 3C).  
An mRNA synthesis inhibitor actinomycin D (1 μg/ml) produced a similar effect to that of 
cycloheximide, negating thrombin cytotoxicity in the cortical region almost completely (Fig. 
3D).  These drugs also reversed thrombin-induced shrinkage of the striatal region (Fig. 3F).  
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Third, we examined possible involvement of caspase-3, an executioner caspase involved in 
apoptotic cell death induced by various stimuli (Leist and Jäättelä, 2001).  Concurrent 
application of cell-permeable DEVD-CHO, a caspase-3 inhibitor, did not produce any effects 
on thrombin-induced cell death in the cortical region and shrinkage of the striatal region (Fig. 
3E, G).  These results suggest that thrombin-induced injury requires de novo protein 
synthesis but not caspase-3 activity. 
 
Differential involvement of protease activity and PAR-1 in thrombin toxicity in the cortex and 
in the striatum 
We examined if protease activity of thrombin and activation of thrombin receptors were 
responsible for thrombin cytotoxicity.  PARs, after removal of their amino-terminal domain 
by protease activity of thrombin, mediate various biological actions of thrombin (Noorbakhsh 
et al., 2003).  However, thrombin may also exert some of its biological effects through 
protease activity- and/or PAR-independent mechanisms (Tran and Stewart, 2003; Hanisch et 
al., 2004). 
We tested the effect of argatroban, a drug that inhibits enzymatic activity of thrombin by 
binding to the hydrophobic pocket (Kikumoto et al., 1984).  We found that argatroban (30 - 
300 μM) significantly but only partially attenuated thrombin cytotoxicity in the cortical 
region (Fig. 4A).  On the other hand, argatroban (300 μM) completely blocked 
thrombin-induced shrinkage of the striatal region (Fig. 4D).  Notably, prior heat inactivation 
of thrombin only weakly inhibited thrombin cytotoxicity at 48 h and had no effect at 72 h in 
the cortical region (Fig. 4C), whereas the same procedure abolished induction of shrinkage of 
the striatal region by thrombin (Fig. 4F).  Moreover, we examined the effect of a PAR-1 
antagonist FR171113 (Kato et al., 2003).  FR171113 (300 μM) did not inhibit 
thrombin-induced cell death in the cortical region (Fig. 4B), whereas the drug significantly 
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inhibited thrombin-induced shrinkage of the striatal region (Fig. 4E).  These results suggest 
that cytotoxicity of thrombin in the striatum is dependent on the protease activity of thrombin 
and activation of PAR-1, whereas cytotoxicity of thrombin in the cerebral cortex involves 
protease activity-independent mechanisms. 
In hippocampal neurons, thrombin has been reported to potentiate NMDA receptor 
function via activation of PAR1 (Gingrich et al., 2000).  To clarify if NMDA receptors are 
involved in thrombin toxicity, we examined the effect of MK-801.  Co-application of 10 μM 
MK-801 with 100 U/ml thrombin did not prevent either cortical injury or striatal shrinkage 
(data not shown). 
 
MAPKs are differentially involved in thrombin toxicity in the cortex and in the striatum 
Distinct classes of MAPKs such as ERK, p38 MAPK and JNK play important roles in 
regulation of neuronal survival and death (Colucci-D’Amato et al., 2003; Davis, 2000: Gallo 
and Johnson, 2002).  Because several members of MAPK family have been reported to 
mediate various biological responses induced by thrombin (Möller et al., 2000; Suo et al., 
2003; Wang et al., 2002), we examined the effects of MAPK inhibitors on thrombin 
cytotoxicity in cortico-striatal slice cultures.  PD98059 (10 - 100 μM) and U0126 (1 - 10 
μM), drugs that compromise ERK activation by inhibiting mitogen/extracellular 
signal-regulated kinase (MEK), significantly reduced thrombin-induced cell death in the 
cortical region (Fig. 5B, C, F, G).  On the other hand, SB203580 (10 - 100 μM), an inhibitor 
of p38 MAPK, did not inhibit thrombin cytotoxicity in the cortical region (Fig. 5D, H).  The 
cytotoxicity of SB203580 per se, as evident in Fig. 5D, was not consistently observed in the 
other sets of experiments.  Notably, SP600125 (10 - 100 μM), a JNK inhibitor, strongly 
potentiated thrombin cytotoxicy in the cortex (Fig. 5E, I).  However, all of these inhibitors of 
MAPK pathways markedly attenuated thrombin-induced shrinkage of the striatal region (Fig. 
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5J).  These results indicate that ERK is involved in thrombin-induced neuronal death in the 
cortex, whereas ERK, p38 and JNK are involved in thrombin-induced shrinkage of the 
striatum. 
 
Involvement of microglia in thrombin cytotoxicity  
We further examined potential involvement of other signal mediators in thrombin 
cytotoxicity.  In the midbrain substantia nigra, thrombin toxicity on dopaminergic neurons 
appears to be mediated by microglia producing cytotoxic mediators including nitric oxide 
(NO) (Choi et al., 2003a).  In addition, a recent report showed that thrombin-induced 
damage in the hippocampus was mediated by reactive oxygen species produced from 
microglia (Choi et al., 2005).  Accordingly, we tested the effects of NO synthase inhibitors 
and antioxidants on thrombin cytotoxicity.  We indeed found that cytotoxic concentrations 
(100 - 300 U/ml) of thrombin increased NO production from cortico-striatal slice cultures at 
48 - 72 h (Fig. 6A, B).  The increase in NO production was almost completely blocked by 
NO synthase inhibitors aminoguanidine and L-NAME, each at 300 μM (data not shown).  
However, these inhibitors did not produce significant protective effects against 
thrombin-induced cell death in the cortical region (Fig. 6C for the data on L-NAME) and 
shrinkage of the striatal region (Fig. 6D).  Moreover, antioxidants glutathione (data not 
shown) and NAC (Fig. 6E, F) were also without effect against thrombin toxicity in the cortex 
and in the striatum.  Activated microglia may also produce potentially cytotoxic factors other 
than NO and reactive oxygen species.  Therefore, we collected conditioned medium of slice 
cultures treated with 100 U/ml thrombin for 72 h, and treated another set of slice cultures with 
the conditioned medium.  The potency of cytotoxicity of the conditioned medium was the 
same as that of fresh culture medium containing 100 U/ml thrombin (data not shown).  
These results do not support the proposal that diffusible cytotoxic factors are released in 
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response to thrombin. 
Next we examined the effect of clodronate, a drug shown to deplete microglia from brain 
slice cultures (Kohl et al., 2003).  We confirmed that slice cultures treated with clodronate 
(100 μg/ml) and thrombin had much fewer microglia than cultures treated with thrombin 
alone (Fig. 6G, H).  In addition, cultures treated with clodronate and thrombin produced a 
smaller amount of nitrite than cultures treated with thrombin alone (11.7 ± 1.0 μM, n = 3 and 
32.8 ± 5.0 μM, n = 4, with or without clodronate, respectively; P < 0.01).  However, 
clodronate did not affect the degree of thrombin-induced injury in the cortical region (Fig. 6I).  
These results suggest that microglial activation does not contribute to cortical injury by 
thrombin.  Interestingly, thrombin-induced shrinkage of the striatal region was significantly 
inhibited by clodronate treatment (Fig. 6J). 
 
Thrombin cytotoxicity is regulated by Src and protein kinase C 
Thrombin-induced activation of ERK in cultured astrocytes is regulated by several 
upstream signaling molecules including Src protein tyrosine kinase and PKC (Wang et al., 
2002; Wang and Reiser, 2003).  Considering that ERK activation plays a key role in 
thrombin cytotoxicty (Fig. 5), we examined possible involvement of Src and PKC.  
Concurrent application of PP2 (10-100 μM), an inhibitor of Src, with thrombin reduced cell 
injury in the cortical region in a concentration-dependent manner (Fig. 7A, B, D).  In 
contrast, AG490, an inhibitor of JAK2 protein tyrosine kinase, did not show any protective 
effect at concentrations up to 100 μM (data not shown).  We also found that BIM (0.3 - 3 
μM), an inhibitor of PKC, prevented thrombin-induced cell injury in the cortical region 
(Fig.7C, E).  PP2 and BIM were also effective in inhibiting thrombin-induced shrinkage of 
the striatal region (Fig. 7F).  Together, these results suggest that Src and PKC contribute to 
thrombin cytotoxicity. 
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 Thrombin induces rapid ERK phosphorylation independently of Src and protein kinase C 
We next examined the time course of ERK phosphorylation in response to thrombin by 
western blot analysis.  Levels of phosphorylated ERK increased promptly after thrombin 
application, peaked at 1 - 3 h and gradually declined thereafter (Fig. 8A, B).  To determine 
cell types exhibiting ERK phosphorylation after 3 h of thrombin treatment, we performed 
double immunofluorescence staining with a combination of antibodies against phoshorylated 
ERK and cell type-specific marker proteins.  Immunostaining with the neuronal marker 
NeuN revealed that many of the phospho-ERK-positive cells were neurons (Fig. 8C-E).  We 
could not determine whether these phospho-ERK-positive neurons corresponded to ultimately 
dying cells, because ERK phosphorylation declined before cell death became prominent.  
We also observed co-localization of phospho-ERK with the microglia marker OX42 (Fig. 8F) 
and with the astrocyte marker GFAP (Fig. 8G).  However, the glial population positive for 
phospho-ERK was much smaller than phospho-ERK-positive neuronal population. 
We examined the effects of inhibitors of Src and PKC on thrombin-induced ERK 
phosphorylation, to determine if these signaling molecules act upstream of ERK activation.  
As expected, the MEK inhibitor PD98059 (100 μM) abolished thrombin-induced increase in 
ERK phosphorylarion.  In sharp contrast, the Src inhibitor PP2 at 100 μM, a concentration 
that significantly reduced thrombin cytotoxicity (Fig. 7), showed no effect on 
thrombin-induced ERK phosphorylation.  In addition, the PKC inhibitor BIM (3 μM) did not 
inhibit, but rather, potentiated ERK phosphorylation (Fig. 8H, I).  These results indicate that 
thrombin induces ERK phosphorylation in Src- and PKC-independent manner, and also that 
Src and PKC regulate thrombin cytotoxicity independently of ERK regulation. 
Although ERK was phosphorylated promptly after thrombin exposure, cell injury in the 
cortical region and shrinkage of the striatal region occurred with a long delay (see Fig. 1).  
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Therefore, we examined whether these detrimental effects could be triggered by a shorter 
period of thrombin exposure.  Exposure of the cultures to thrombin for 24 h followed by 
incubation in thrombin-free medium did not induce significant cell death in the cortical region.  
Robust cell death was induced when the period of thrombin application was extended to 36 h 
or longer (Fig. 9A).  Shrinkage of the striatal region was induced by 24 h exposure to 
thrombin followed by 48 h of post-incubation in thrombin-free medium.  However, longer 
periods of exposure such as 48 h were required for thrombin to fully exert the detrimental 
effect (Fig. 9B).  These results suggest that persistent signaling, in addition to rapid ERK 
phosphorylation, is required for induction of cell death by thrombin. 
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Discussion 
Accumulating evidence indicates that thrombin exerts deleterious effects in the central 
nervous system under several pathological conditions including intracerebral hemorrhage 
(Gingrich and Traynelis, 2000; Xi et al., 2003).  Because thrombin receptors are expressed 
not only in neurons but also in astrocytes and microglia (Grabham and Cunnnigham, 1995; 
Suo et al., 2002), thrombin extravasation should mobilize complicated processes that lead to 
cellular injury.  In this study we used organotypic cortico-striatal slice cultures to evaluate 
cytotoxicity of thrombin, and found that prolonged application of thrombin produces 
cytotoxic effects with a delayed onset.  Thrombin showed robust cytotoxic actions at 100 
U/ml.  This is a concentration attainable in the case of hemorrhagic injury, because 
prothrombin in 100 μl of blood is estimated to produce ~30 U thrombin (Xi et al., 2003).  
Histochemical examinations revealed that dying cells in the cortical region of slice cultures 
after thrombin treatment consisted mainly of neurons and also included some microglia but 
not astrocytes, although thrombin causes cell death in astrocytes as well as neurons in 
dissociated cell culture preparations (Donovan et al., 1997).  In addition to robust cell death 
in the cortical region, thrombin caused shrinkage of the cultured tissue, particularly in the 
striatal region.  The striatal shrinkage is a unique feature of thrombin cytotoxicity, because 
we have not observed shrinkage of the tissues in response to other cytotoxic insults we tested 
so far, including NMDA and oxygen-glucose deprivation (Fujimoto et al., 2004). 
Apoptotic cell death is accompanied by morphological changes in cell nuclei such as 
condensation and fragmentation.  In addition, macromolecule synthesis is required for many, 
if not all, cases of apoptotic cell death (Holcik and Sonenberg, 2005).  Previous reports have 
demonstrated that thrombin induces nuclear fragmentation, and cycloheximide prevents 
thrombin-induced cell death in cultured hippocampal neurons (Donovan et al., 1997).  In line 
with these observations, we observed that numerous cells in the cortical region exhibited 
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nuclear fragmentation in response to thrombin, and also that cycloheximide and actinomycin 
D prevented thrombin toxicity in the cortex and in the striatum.  On the other hand, a 
caspase-3 inhibitor did not inhibit thrombin cytotoxicity, although the involvement of this 
executioner caspase in thrombin-induced apoptosis has been suggested in cultured motor 
neurons (Turgeon et al., 1998) and in midbrain dopaminergic neurons in vivo (Choi et al., 
2003a).  In this context, apoptosis-like cell death in the absence of caspase activation has 
been documented (Leist and Jäättelä, 2001; Sperandio et al., 2000).  A recent report showed 
that ERK activation led to nuclear condensation and cell death of rat cerebellar granule 
neurons, which was independent of caspase-3 (Subramaniam et al., 2004). 
Although thrombin induced delayed injury both in the cerebral cortex and in the striatum, 
underlying mechanisms of thrombin cytotoxicity were different between these brain regions.  
In the striatal region, the actions of thrombin are likely to be mediated by its protease activity 
and activation of PAR-1, since thrombin-induced shrinkage of the striatal region was 
abolished by argatroban as well as by heat inactivation of thrombin, and was significantly 
inhibited by a PAR-1 antagonist.  In contrast, argatroban only partially inhibited 
thrombin-induced cortical cell death, and heat inactivation of thrombin and co-application of 
a PAR-1 antagonist were without effect.  Protease activity-independent action of thrombin 
has been reported in the case of microglial activation (Hanisch et al., 2004).  Moreover, 
PAR-independent actions of thrombin have been reported in airway smooth muscle cells 
(Tran and Stewart, 2003).  How thrombin can exert biological actions independently of its 
protease activity is unclear, but thrombin may somehow activate several signaling pathways 
including ERK, Src and PKC, as discussed below. 
We showed here that ERK activation plays an important role in thrombin cytotoxicity, 
based on the observation that inhibition of ERK phosphorylation by MEK inhibitors 
significantly attenuated thrombin-induced cell death in the cortical region and shrinkage of 
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the striatal region.  Protective effect of MEK inhibitors against thrombin cytotoxicity has 
been previously demonstrated in cultured hippocampal cell line (Suo et al., 2003) and in 
midbrain dopaminergic neurons in vivo (Choi et al., 2003a).  We additionally found that 
inhibition of p38 did not affect, whereas inhibition of JNK exacerbated, thrombin-induced 
cortical cell death.  Generally, JNK activation is linked to apoptotic cell death induced by 
various stimuli including nerve growth factor deprivation (Ham et al., 1995) and excitatory 
amino acids (Borsello et al., 2003), but neuroprotection by JNK activation through the 
mechanisms involving astrocyte-derived diffusible factors have also been reported 
(Dhandapani et al., 2003).  Elucidation of detailed regulatory mechanisms of thrombin 
cytotoxicity by JNK requires further investigation.  What is more interesting is that 
inhibitors of MEK, p38 and JNK all attenuated thrombin-induced shrinkage of the striatal 
region, which indicates that multiple members of MAPK family are involved in striatal 
degeneration induced by thrombin.  These results also suggest that thrombin recruits 
different signaling mechanisms leading to cellular injury in different brain regions. 
Thrombin can activate microglia (Ryu et al., 2000; Suo et al., 2002), and microglial 
activation may constitute an important aspect of thrombin-induced degeneration of midbrain 
dopaminergic neurons (Choi et al., 2003a) and hippocampal neurons (Choi et al., 2005) in 
vivo.  In addition, microglia-induced neuronal injury may be mediated by production of NO 
and reactive oxygen species (Choi et al., 2003a, 2005).  However, we did not observe 
significant protective effect of NO synthase inhibitors and antioxidants against 
thrombin-induced injury in the cerebral cortex and in the striatum.  Moreover, depletion of 
microglia by clodronate did not prevent thrombin cytotoxicity in the cortical region.  
Therefore, in the cortical region, thrombin is likely to produce cytotoxic effects by directly 
acting on neurons, rather than by indirectly acting through microglial activation, although the 
contribution of glial cells to neuronal degeneration cannot be entirely excluded.  The fact 
21 
that the majority of phospho-ERK-positive cells after thrombin treatment were neurons is also 
consistent with this proposal.  In contrast, thrombin toxicity in the striatal region was 
significantly inhibited by clodronate.  These observations reveal another difference between 
the cerebral cortex and the striatum with respect to thrombin-induced injury. 
Src and PKC were shown to act upstream of ERK phosphorylation in thrombin signaling 
pathway leading to proliferation of astrocytes (Wang et al., 2002; Wang and Reiser, 2003) and 
oligodendrocytes (Lin et al., 2005).  Based on the assumption that ERK phosphorylation 
leading to thrombin-induced cell death might also be regulated by Src and PKC, we examined 
potential involvement of these signaling molecules in thrombin cytotoxicity.  We found that 
inhibitors of Src and PKC significantly prevented thrombin-induced cell injury.  
Unexpectedly, however, these inhibitors did not prevent thrombin-induced ERK 
phosphorylation.  Therefore, Src and PKC are involved in the signaling cascade leading to 
neuronal death, independently of regulation of ERK activation.  In this context, protein 
tyrosine kinase-independent ERK phosphorylation in response to thrombin has been 
hypothesized in platelets (Tulasne et al., 2002). 
Involvement of signaling pathways other than ERKs in thrombin cytotoxicity was also 
suggested by comparison of the time course of ERK phosphorylation with the period of 
application required for thrombin cytotoxicity.  ERK phosphorylation was promptly induced 
by thrombin application, peaked at 1 - 3 h and then declined gradually, whereas prolonged 
treatment (36 h or more) was required for full development of cell death by thrombin.  
Therefore, ERK activation per se may be unable to trigger cell injury, and other persistent 
signaling mechanisms are also essential for thrombin cytotoxicity.  Whether Src and/or PKC 
correspond to this persistent signaling remains to be determined. 
In this study, we revealed that complex signaling mechanisms underlie the cytotoxic 
actions of thrombin in cortico-striatal tissues.  Cytotoxic signaling recruited by thrombin 
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appears to be different between different brain regions, but we also showed here that ERK 
activation mediates thrombin cytotoxicity both in the cortex and in the striatum.  ERK 
activation occurs during the early phase of thrombin exposure, which leads to delayed 
neuronal death displaying several apoptosis-like features.  Elucidation of the detailed 
mechanisms of thrombin signaling during induction of neuronal death, in particular the 
downstream targets of ERKs, may present a novel strategy of therapeutic interventions against 
intracerebral hemorrhage and other neuropathological conditions. 
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Figure Legends 
Fig. 1.  Thrombin-induced cortical cell injury and striatal shrinkage.  (A-L) Representative 
images of PI fluorescence of whole cultured slices exposed to vehicle (A, D, G, J), 100 U/ml 
thrombin (B, E, H, K) and 300 U/ml thrombin (C, F, I, L) for 0 h (before exposure), 24 h, 48 h 
and 72 h, respectively.  Broken lines in panels A-C and J-L indicate areas of the cerebral 
cortex (Cx) and the striatum (St).  Scale bar, 1 mm.  (M) An image of PI fluorescence of 
another slice culture exposed to 100 U/ml thrombin for 72 h.  (N) An image at a high 
magnification of the region indicated by the solid line in panel M.  The asterisk (*) indicates 
the area of the striatal region detaching from the membrane.  Scale bar, 200 μm.  (O, P) 
Representative images of PI fluorescence of whole cultured slices exposed to 100 μM NMDA 
for 0 h (M) and 72 h (N).  (Q) Thrombin-induced cortical cell injury as assessed by intensity 
of PI fluorescence.  Thrombin at indicated concentrations were applied for indicated periods.  
## P < 0.01, ### P < 0.001 vs. vehicle (veh) at respective time points (n = 5-6).  (R) 
Thrombin-induced striatal shrinkage as assessed by measurement of the striatal area.  
Thrombin at indicated concentrations were applied for indicated periods.  * P < 0.05, *** P 
< 0.001 vs. 0 h of respective treatment (n = 12). 
 
Fig. 2.  (A-F) Confocal images of the cortical region of slice cultures exposed to vehicle (A, 
C, E) and thrombin (100 U/ml) (B, D, F) for 72 h and immunostained for cell type-specific 
markers.  PI fluorescence (red) was colocalized with Neu N and OX42 immunoreactivity 
(green, B, D), markers of neurons and microglia, respectively, but not with GFAP 
immunoreactivity (green, F), a marker of astrocytes.  Arrowheads indicate colocalization of 
immunoreactivity with PI.  Arrows in B indicate PI-positive and weakly Neu N-stained cells, 
reflecting progression of degeneration processes.  (G, H) Fluorescence-labeled NeuN 
immunoreactivity (red) and fluorescence-labeled isolectin GS-IB4 (green) in the cortical 
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region of slice cultures exposed to 100 U/ml thrombin for 48 h (G) and 72 h (H).  No 
engulfing activity of isolectin-positive microglia against neuronal nuclei was evident.  Scale 
bar, 20 μm.   
 
Fig. 3.  Thrombin-induced cell injury accompanies nuclear fragmentation, and is dependent 
on new protein synthesis but not on caspase activity.  (A, B) Nuclear morphology in the 
cortical region as revealed by Hoechst 33342 staining, after treatment of slice cultures with 
vehicle (A) and 100 U/ml thrombin (B) for 72 h.  Arrowheads indicate nuclear 
fragmentation.  Scale bar, 50 μm.  (C-E) Effects of cycloheximide (CHX; C), actinomycin 
D (AD; D) and DEVD-CHO (DEVD; E) on thrombin-induced cell injury in the cortical 
region.  Drugs at indicated concentrations were concomitantly applied with 100 U/ml 
thrombin, and cell death was assessed at 48 and 72 h.  (F, G) Effects of CHX, AD (F) and 
DEVD (G) on thrombin (100 U/ml)-induced shrinkage of the striatal region at 72 h.  # P < 
0.05, ### P < 0.001 vs. vehicle, * P < 0.05, ** P < 0.01, *** P < 0.001 vs. thrombin alone. 
 
Fig. 4.  Involvement of protease activity and PAR-1 activation in thrombin cytotoxicity.  
(A-C) Effects of argatroban (A), FR171113 (B) and heat inactivation (C) on thrombin-induced 
cell injury in the cortical region.  Argatroban at indicated concentrations was applied 
concomitantly with 100 U/ml thrombin.  FR171113 was applied at indicated concentrations 
from 24 h before and during thrombin application.  “H” indicates heat treatment of drug 
solution achieved by incubation in boiling water for 15 min.  (D-F) Effects of argatroban 
(ARG, 300 μM; D), FR171113 (FR, 300 μM; E) and heat inactivation (F) on thrombin (100 
U/ml)-induced shrinkage of the striatal region at 72 h.  ## P < 0.01, ### P < 0.001 vs. vehicle, 
* P < 0.05, ** P < 0.01, *** P < 0.001 vs. thrombin alone. 
 
31 
Fig. 5.  Differential involvement of MAPKs in thrombin toxicity in the cortex and in the 
striatum.  (A-E) Representative images of PI fluorescence of whole cultured slices exposed 
for 72 h to 100 U/ml thrombin alone (A), thrombin plus PD98059 (100 μM; B), U0126 (10 
μM; C), SB203580 (100 μM; D) or SP600125 (100 μM; E).  Scale bar, 1 mm.  (F-I) Effects 
of MAPK inhibitors on thrombin-induced cell injury in the cortical region.  PD98059 (F), 
U0126 (G), SB203580 (H) and SP600125 (I) at indicated concentrations were concomitantly 
applied with 100 U/ml thrombin, and cell death was assessed at 48 and 72 h.  (J) Effects of 
MAPK inhibitors at the highest concentration examined on thrombin (100 U/ml)-induced 
shrinkage of the striatal region at 72 h.  # P < 0.05, ### P < 0.001 vs. vehicle, * P < 0.05, ** 
P < 0.01, *** P < 0.001 vs. thrombin alone. 
 
Fig. 6.  Involvement of nitric oxide production, oxidative stress and microglia activation in 
thrombin toxicity.  (A, B) Concentration- and time-dependent accumulation of nitrite in 
culture medium in response to thrombin.  In (A), nitrite levels were determined after 72 h of 
treatment with indicated concentrations of thrombin.  In (B), nitrite levels were determined 
after indicated periods of treatment with 100 U/ml thrombin.  (C) Effects of L-NAME on cell 
injury in the cortical region.  L-NAME at indicated concentrations was concomitantly 
applied with 100 U/ml thrombin, and cell death was assessed at 48 and 72 h.  (D) Effects of 
aminoguanidine (AG, 300 μM) and L-NAME (300 μM) on thrombin (100 U/ml)-induced 
shrinkage of the striatal region at 72 h.  (E) Effect of NAC on thrombin-induced cell injury 
in the cortical region.  NAC at indicated concentrations was concomitantly applied with 100 
U/ml thrombin, and cell death was assessed at 48 and 72 h.  (F) Effects of NAC (1 mM) on 
thrombin-induced shrinkage of the striatal region at 72 h.  (G-J) Effect of clodronate on 
microglia population and thrombin toxicity.  Clodronate was applied to slice cultures from 
72 h before and during treatment with vehicle or thrombin.  Slice cultures exposed to 
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thrombin for 72 h in the absence (G) or presence (H) of clodronate (100 μg/ml) were 
immunostained for OX42, a marker of microglia.  Scale bar, 50 μm.  Clodronate (10 – 100 
μg/ml) did not protect the cortical region from thrombin-induced injury (I), but striatal 
shrinkage was prevented by 100 μg/ml clodronate (CLO; J).  ## P < 0.01, ### P < 0.001 vs. 
vehicle, *** P < 0.001 vs. thrombin alone. 
 
Fig. 7.  Effects of inhibitors of Src and PKC on thrombin cytotoxicity.  (A-C) 
Representative images of PI fluorescence of whole cultured slices exposed to 100 U/ml 
thrombin alone (A), and thrombin plus PP2 (100 μM; B) or BIM (3 μM; C) for 72 h.  Scale 
bar, 1 mm.  (D, E) Effects of inhibitors of Src and PKC on thrombin-induced cell injury in 
the cortical region.  PP2 (D) and BIM (E) at indicated concentrations were concomitantly 
applied with 100 U/ml thrombin, and cell death was assessed at 48 and 72 h.  (F) Effects of 
inhibitors of Src and PKC at the highest concentration examined on thrombin (100 
U/ml)-induced shrinkage of the striatal region at 72 h.  ## P < 0.01, ### P < 0.001 vs. vehicle, 
* P < 0.05, ** P < 0.01, *** P < 0.001 vs. thrombin alone. 
 
Fig. 8.  Thrombin-induced phosphorylation of ERKs.  (A) Representative blots of ERK 
phosphorylation in response to thrombin.  Homogenates were prepared from whole slice 
cultures treated with thrombin (100 U/ml) for indicated periods and lysates were subjected to 
western blot analysis with specific antibodies against phosphorylated ERK, total ERK and 
actin.  Slices without thrombin treatment (0 h) were used as control.  (B) Time course of 
ERK phosphorylation.  Ratio of phospho-ERK versus total ERK at each time point was 
normalized by the ratio at time 0.  # P < 0.05, ## P < 0.01, ### P <0.001 vs. time 0 (n = 5).  
(C-G) Confocal microscopic images of immunofluorescence of phospho-ERK (C), Neu N (D) 
and their merged image (E), and merged images of phospho-ERK (green) and OX42 (red, F) 
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or GFAP (red, G), after 3 h of treatment with 100 U/ml thrombin.  Arrowheads indicate 
co-localization.  Scale bar, 20 μm.  (H) Representative blots showing the effects of drugs on 
thrombin-induced ERK phosphorylation.  Western blot analysis was performed on slice 
cultures that received no treatment (NT), vehicle treatment (V), 100 U/ml thrombin with or 
without PD98059 (PD; 100 μM), PP2 (100 μM) and BIM (3 μM) for 3 h.  (I) Summary of 
the effects of drugs on ERK phosphorylation.  # P < 0.05 vs. no treatment, * P < 0.05 vs. 
thrombin alone (n = 4). 
 
Fig. 9.  Persistent signaling is required for induction of cell death by thrombin.  Slice 
cultures were treated with 100 U/ml thrombin for hours indicated on the left side of slash (/) 
and subsequently incubated without thrombin for hours indicated on the right side of slash.  
Cell injury in the cortical region (A) and shrinkage of the striatal region (B) were assessed at 
72 h after the onset of treatments.  ### P < 0.001 vs. vehicle (indicated as “0/72”). 
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